Nfocus Neuromedical Obtains CE Mark Approval for CardioVasc Advantage

August 12, 2009—Nfocus Neuromedical Inc. (Palo Alto, CA) announced that its CardioVasc Advantage vascular reconstruction device has been granted CE Mark approval. The CardioVasc Advantage has been cleared in Europe for the treatment of coronary artery perforations, aneurysms, and saphenous vein graft lesions. The technical platform behind this device will pave the way for future Nfocus neurovascular products currently in development, the company stated. The European approval gives Nfocus the ability to market this advanced system for the treatment of serious coronary vascular indications. The device's design allows it to attain more distal placement with less vessel trauma, the company stated.